
Boehringer Ingelheim has abandoned its hepatitis C (HCV) drug development programme as a dead loss after ‘re-evaluating’ its strategy. The …
Boehringer Ingelheim’s hepatitis C candidate faldaprevir has moved a potential step closer to market with the news that the European …
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer

